Terms: = Lung cancer AND MSH6, GTBP, P52701, 2956, ENSG00000116062, HSAP, HNPCC5 AND Treatment
14 results:
1. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
2. Predictive biomarkers of immunotherapy response with pharmacological applications in solid tumors.
Kovács SA; Fekete JT; Győrffy B
Acta Pharmacol Sin; 2023 Sep; 44(9):1879-1889. PubMed ID: 37055532
[TBL] [Abstract] [Full Text] [Related]
3. Primary Tumor Resection for Stage IV Non-small-cell lung cancer Without Progression After First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor treatment: A Retrospective Case-Control Study.
Kuo SW; Chen PH; Lu TP; Chen KC; Liao HC; Tsou KC; Tsai TM; Lin MW; Hsu HH; Chen JS
Ann Surg Oncol; 2022 Aug; 29(8):4873-4884. PubMed ID: 35254583
[TBL] [Abstract] [Full Text] [Related]
4. The influence of STK11 mutation on acquired resistance to immunotherapy in advanced non-small cell lung cancer with Lynch syndrome: a case report and literature review.
Long Y; Tang Y; Cai C; Yu M; Zhang M; Chen R; Huang M
Ann Palliat Med; 2021 Jun; 10(6):7088-7094. PubMed ID: 33832284
[TBL] [Abstract] [Full Text] [Related]
5. Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal cancer Post-Pembrolizumab.
Das S; Allen A; Berlin J
Clin Colorectal Cancer; 2020 Jun; 19(2):137-140. PubMed ID: 32146081
[TBL] [Abstract] [Full Text] [Related]
6. Role of evaluating tumor‑infiltrating lymphocytes, programmed death‑1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma.
Losi L; Bertolini F; Guaitoli G; Fabbiani L; Banchelli F; Ambrosini-Spaltro A; Botticelli L; Scurani L; Baldessari C; Barbieri F; Cascinu S; Maiorana A
Int J Oncol; 2019 Nov; 55(5):1157-1164. PubMed ID: 31545419
[TBL] [Abstract] [Full Text] [Related]
7. Loss of hypermethylated in cancer 1 (HIC1) promotes lung cancer progression.
Li Y; Yao M; Wu T; Zhang L; Wang Y; Chen L; Fu G; Weng X; Wang J
Cell Signal; 2019 Jan; 53():162-169. PubMed ID: 30312658
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of histone deacetylases sensitizes EGF receptor-TK inhibitor-resistant non-small-cell lung cancer cells to erlotinib in vitro and in vivo.
Yu W; Lu W; Chen G; Cheng F; Su H; Chen Y; Liu M; Pang X
Br J Pharmacol; 2017 Oct; 174(20):3608-3622. PubMed ID: 28749535
[TBL] [Abstract] [Full Text] [Related]
9. Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report.
Gohda Y; Noguchi R; Horie T; Igari T; Nakamura H; Ohta Y; Yamaguchi K; Ikenoue T; Hatakeyama S; Yusa N; Furukawa Y; Yano H
BMC Med Genet; 2016 Dec; 17(1):94. PubMed ID: 27938333
[TBL] [Abstract] [Full Text] [Related]
10. Automatically gated image-guided breath-hold IMRT is a fast, precise, and dosimetrically robust treatment for lung cancer patients.
Simeonova-Chergou A; Jahnke A; Siebenlist K; Stieler F; Mai S; Boda-Heggemann J; Wenz F; Lohr F; Jahnke L
Strahlenther Onkol; 2016 Mar; 192(3):166-73. PubMed ID: 26780654
[TBL] [Abstract] [Full Text] [Related]
11. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
[TBL] [Abstract] [Full Text] [Related]
12. ERCC1, MLH1, MSH2, msh6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
Ting S; Mairinger FD; Hager T; Welter S; Eberhardt WE; Wohlschlaeger J; Schmid KW; Christoph DC
Clin Lung Cancer; 2013 Sep; 14(5):558-567.e3. PubMed ID: 23810210
[TBL] [Abstract] [Full Text] [Related]
13. Is carboplatin and oral etoposide an effective and feasible regimen in patients with small cell lung cancer?
Pfeiffer P; Sørensen P; Rose C
Eur J Cancer; 1995; 31A(1):64-9. PubMed ID: 7695981
[TBL] [Abstract] [Full Text] [Related]
14. Phase I clinical investigation of amonafide.
Saez R; Craig JB; Kuhn JG; Weiss GR; Koeller J; Phillips J; Havlin K; Harman G; Hardy J; Melink TJ
J Clin Oncol; 1989 Sep; 7(9):1351-8. PubMed ID: 2549205
[TBL] [Abstract] [Full Text] [Related]
